Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

L.J.M. Mekenkamp, J. de Nooy-van Tol, J.R. Dijkstra, I. de Krijger, M.E. Vink-Borger, S. van Vliet, S. Teerenstra, E. Kamping, E. Verwiel, M. Koopman, G.A. Meijer, J.H.J.M. van Krieken, R. Kuiper, C.J.A. Punt, I.D. Nagtegaal

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Article number292
JournalBMC Cancer
Volume12
DOIs
Publication statusPublished - 2012

Cite this

Mekenkamp, L. J. M., de Nooy-van Tol, J., Dijkstra, J. R., de Krijger, I., Vink-Borger, M. E., van Vliet, S., ... Nagtegaal, I. D. (2012). Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer, 12, [292]. https://doi.org/10.1186/1471-2407-12-292